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ABSTRACT
Purpose: An increase in the activity of the mitogen-
activated protein kinases (MAPKs) has been correlated
with a more malignant phenotype in several tumor models
in vitro and in vivo. A key regulatory mechanism of the
MAPKs [extracellular signal-regulated kinase (ERK); c-
jun NH2-terminal kinase (JNK); and p38] is the dual
specificity phosphatase CL100, also called MAPK phos-
phatase-1 (MKP-1). This study was designed to examine
the involvement of CL100/MKP-1 and stress-related
MAPKs in lung cancer.
Experimental Design: We assessed the expression of
CL100/MKP-1 and the activation of the MAPKs in a panel
of 18 human cell lines [1 primary normal bronchial epithe-
lium, 8 non-small cell lung cancer (NSCLC), 7 small cell
lung cancer (SCLC), and 2 carcinoids] and in 108 NSCLC
surgical specimens.
Results: In the cell lines, CL100/MKP-1 expression was
substantially higher in NSCLC than in SCLC. P-ERK, P-
JNK, and P-p38 were activated in SCLC and NSCLC, but
the degree of their activation was variable. Immunohisto-
chemistry in NSCLC resection specimens showed high levels
of CL100/MKP-1 and activation of the three MAPK com-
pared with normal lung. In univariate analysis, no relation-
ship was found among CL100/MKP-1 expression and P-
ERK, P-JNK, or P-p38. Interestingly, high CL100/MKP-1
expression levels independently predicted improved survival
in multivariate analysis. JNK activation associated with T1–2
and early stage, whereas ERK activation correlated with late
stages and higher T and N. Neither JNK nor ERK activation
were independent prognostic factors when studied for pa-
tient survival.
Conclusions: Our data indicate the relevance of
MAPKs and CL100/MKP-1 in lung cancer and point at
CL100/MKP-1 as a potential positive prognostic factor in
NSCLC. Finally, our study supports the search of new mo-
lecular targets for lung cancer therapy within the MAPK
signaling pathway.
INTRODUCTION
The mitogen-activated protein kinase (MAPK) pathway
is one of the most important intracellular signaling cascades
conserved from yeast to mammals (1). MAPKs are a family
of serine/threonine kinases in which three main components
are the extracellular signal-regulated kinase (ERK), c-jun
NH2-terminal kinase (JNK), and p38 (2, 3). Activation of any
of the MAPK family members requires phosphorylation of
two regulatory residues (a threonine and a tyrosine) by their
upstream kinases (1, 4). Dephosphorylation of one or both of
these regulatory residues induces deactivation of MAPK fam-
ily members. MAPK dephosphorylation is carried out by
some phosphatases, similar to the dual specificity MAPK
phosphatases (MKPs), which simultaneously dephosphoryl-
ate both serine/threonine and tyrosine residues (5, 6). The
first characterized member of this family was the MKP-1 (or
CL100; Ref. 7). It is encoded by an early response gene,
which is transiently induced by mitogens and stress signals
such as serum, cytokines, UV radiation, heat shock, and
hypoxia (7–11). MAPK phosphatase-1 (CL100/MKP-1) ex-
pression is induced by some of the members of the MAPK
family (12) and other protein kinases (13–15). Although
ERK, JNK, and p38 are known substrates of CL100/MKP-1,
the ability to dephosphorylate each one of these kinases
varies depending on the cell system and its environmental
conditions (11, 16, 17).
CL100/MKP-1 has also been correlated with tumorigen-
esis. The reported expression patterns of CL100/MKP-1 in
carcinogenesis change depending on the organ studied. Pros-
tate, colon, and bladder tumors have high CL100/MKP-1
expression in the early phases of carcinogenesis and loss of
expression levels in advanced stage (18). Besides, in prostate
tumors, a correlation between an increased activation of
ERK, JNK, or both and CL100/MKP-1 overexpression has
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been described previously (19). In other cancers such as
breast carcinomas, a high expression of CL100/MKP-1 in
poorly differentiated or late stages has been shown (18).
More recently, we have observed a decreased CL100/MKP-1
expression in ovarian cancer as compared with normal ovar-
ian epithelial tissue (20).
The MAPK pathway has been shown to be very relevant
in human carcinogenesis (21, 22). Activation of ERK has
been reported in lung (23, 24), kidney (25), breast (26, 27),
head and neck (28), liver (29), prostate (30), salivary gland
(31), and skin (32) tumors. We have recently shown that ERK
activation in lung cancer is associated with late stage (33).
Few studies on the activation of JNK and p38 have been
carried out in clinical specimens of cancer patients. Activa-
tion of both JNK and p38 has been found in prostate carci-
noma (34), and deactivation of these kinases has been re-
ported in colon cancer (35, 36) and in advance stages of
prostate carcinoma (34). P-p38 has also been observed in a
few cases of non-small cell lung cancer (NSCLC; Ref. 37).
All these data have contributed to the rationale of developing
inhibitors of the MAPK pathway (38), which are now enter-
ing clinical trials.
CL100/MKP-1 mRNA has been found in normal lung
extracts (10), but little is known about its cellular distribution
and the role of this phosphatase in lung cancer. In addition,
stress-related MAPKs (JNK and p38) have not yet been studied
in lung cancer. Therefore, the aim of this study was to charac-
terize the expression and localization of CL100/MKP-1 and to
explore the possible correlation of CL100/MKP-1 overexpres-
sion and activation of any MAPK. Finally, we also analyzed the
potential relevance of these markers as prognostic factors in
NSCLC.
MATERIALS AND METHODS
Patient Specimens. Surgical specimens of human lung
tumors were collected from a total number of 108 patients.
Ninety-five clinical specimens were obtained from patients of
the University Hospital of Navarra, and 13 samples were ob-
tained from patients of the Canisius Wilhelmina Hospital (Ni-
jmegen, the Netherlands). All of the samples were collected
before any chemo- or radiotherapy schedule. We had clinical
follow-up of 70 of the 108 NSCLC specimens. We also had
normal samples of distant tissue to the tumor or adjacent tissue
to the tumor from approximately one-third of the lung cancer
patients studied. Each specimen was fixed in 10% formalin and
embedded in paraffin. Five-m sections were stained with H&E
for tumor morphology assessment. Two pathologists in our
group evaluated the tumors (M. Lozano and G. Toledo): 43
tumors were adenocarcinomas, and 65 were squamous cell
carcinomas.
All patients with clinical follow-up (70 of 108) had an
Eastern Cooperative Oncology Group performance status of 0 to
2, adequate baseline organ function and no severe co-morbid
conditions. Written-signed informed consent was obtained from
all patients before treatment. The treatment of the 70 patients
was homogeneous as detailed below.
Tumor stage was determined according to the Tumor-
Node-Metastasis staging system. Treatment was different
depending on the stage of the tumor and other characteristics
of the patient. Most patients were treated after a multidisci-
plinary therapeutic approach. In short, surgery was the initial
treatment for medically operable stage I to IIB and IIIA
non-N2 tumors. Lobectomy and ipsilateral mediastinal lymph
node sampling were the treatments of choice. Postoperative radio-
therapy consisting of 45 Gy using conventional fields and fraction-
ation schedules was added depending on pathological findings.
Patients with locally advanced NSCLC were treated with pacli-
taxel- and cisplatin-based chemotherapy previous to radical hyper-
fractionated radiotherapy (69.6 Gy) with concurrent chemotherapy.
Stage IV patients were treated with cisplatin-based chemotherapy.
Median follow-up time of patients was 29.5 months (range, 0.5–68
months).
Cell Culture. Small cell lung cancer (SCLC) cell lines
(NCI-H69, NCI-H82, NCI-H187, NCI-H345, NCI-H510, and
NCI-H774), NSCLC cell lines (NCI-H23, NCI-H157, NCI-
H676, NCI-H1264, and NCI-A549), and carcinoid cell line
(NCI-H720) were obtained from the Department of Cell and
Cancer Biology (National Cancer Institute, NIH, Bethesda,
MD). NCI-H446 (SCLC), NCI-H441, Calu3, HTB-58
(NSCLC), and NCI-H727 (carcinoid) were obtained from the
American Type Culture Collection (Manassas, VA). Normal
human bronchial epithelium (NHBE) primary cells were ob-
tained from Clonetics Corp. (San Diego, CA). All cell lines
were grown in RPMI 1640 with glutamax supplemented with
100 units/ml penicillin, 100 g/ml streptomycin, and 10%
heat-inactivated fetal bovine serum (Life Technologies, Inc.,
Rockville, MD), except for NHBE 2006 that was grown in
bronchial epithelial growth medium (Clonetics Corp.) ac-
cording to the manufacturer’s instructions.
Immunohistochemistry and Immunocytochemistry.
Immunohistochemistry (IHC) was performed on 5-m sec-
tions of formalin-fixed, paraffin-embedded tissues. The poly-
clonal antibodies used in the immunohistochemical studies
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA) (sc-1109) to detect CL100/MKP-1, from Cell Signaling
(Beverly, MA) to detect P-ERK and P-p38, and from Pro-
mega (Madison, WI) to detect P-JNK. Samples were incu-
bated overnight at 4°C with the primary antibody. Immuno-
cytochemical reaction was shown using the EnVision
intensifying kit (Dako, Carpinteria, CA). Absorption controls
with a specific peptide were performed to confirm for spec-
ificity of the CL100/MKP-1 immunostaining. Positive con-
trols for phosphorylated antibodies were stress-activated
HTB58 human lung cancer cells fixed in 10% formalin and
treated with medium containing 20% FBS. MAPK activation
was achieved in positive controls by culturing the cells dur-
ing 16 h in a serum deprived medium (containing 0.4% FBS).
The results were evaluated independently by two observers.
The tumors were scored according to the proportion of nuclei
or cytoplasms stained within the tumor. For CL100/MKP-1
and phospho-JNK, 50% of stained nuclei or cytoplasm of
tumor cells within the specimens were considered positive. In
the case of P-ERK and P-p38, 15% of the nuclei or cyto-
plasms in tumor cells was considered positive. In all cases,
cutoff was chosen according to the median values and used
only for clinical correlation purposes. Data regarding P-ERK
immunostaining were part of a previous study (33), and they
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were used in the present study to analyze their correlation
with CL100 expression levels and with activation of other
MAPKs.
Immunocytochemistry for CL100/MKP-1 of cultured cells
was performed on cell lines fixed in Saccomano’s fixative. Cells
growing attached to the substrate (H23, H441, H446, A549,
H727, H1264, and HTB58) were seeded on glass slides and
grown at a confluence of 60–70%, washed twice with PBS, and
fixed. Cells growing in suspension (H82, H187, H345, H460,
H510, and H720) were centrifuged at 1500 rpm at 4°C in 50-ml
Falcon tubes, washed twice with PBS, and resuspended in
Saccomano’s fixative. Before the immunocytochemistry, the
floating cells were spun down to the slides using a cytospin
(Cytospin 3; Shandon Scientific Limited, Pittsburgh, PA).
Slides were immersed in methanol/acetone (1:1 V/V) for 5 min
and air dried. The staining results for CL100/MKP-1 in the cell
lines were evaluated according to the following criteria: for each
cell line, five high power fields randomly selected were as-
sessed. When the average percentage of the five fields was
50%, immunostaining was considered positive. To avoid var-
iability, the staining and the study of all cell lines were per-
formed at the same time, with the same reagents and incubation
times.
RNA Isolation and Northern Blot Analyses. Total
RNA was extracted from cells growing in exponential phase
with guanidinium isothiocyanate and isolated using a CsCl
gradient protocol. Ten g of total RNA were separated on a
1% agarose gel containing 2.2 M formaldehyde, transferred
by capillary action overnight onto a nitrocellulose membrane
(Schleiner & Schuell, Inc., Dassen, Germany) using a 10
SSC blotting buffer (1.5 M NaCl and 0.15 M trisodium cit-
rate). After the transfer, the membrane was exposed to UV
light for 2 min to immobilize the RNA and hybridized with a
32P-labeled CL100/MKP-1 cDNA probe corresponding to a
SalI/XhoI fragment of human CL100/MKP-1 (from bp 644 to
1001 of CL100 cDNA; GenBank accession no. X68277).
Hybridization was carried out overnight at 42°C in a hybridiza-
tion buffer containing 40% formamide. The hybridized isotopic
signal was detected using Kodak XAR Film, quantitated with a
densitometer (JX-325; SHARP, Buenos Aires, Argentina) and an-
alyzed with Imagemaster 1D software (Amersham Biosciences,
Piscataway, NJ).
Western Blot Analyses. Cells were collected in log
phase and lysed with lysis buffer that contained 25 mM
sodium -glycerophosphate, 25 mM NaF, 1 mM Na3VO4, 1
mM Na2P3O4, 5 mM EDTA, 5 mM EGTA, 1 mM benzamidine,
0.05% sodium deoxycholate (w/v), sodium SDS 0.01% (w/v),
1% Triton X-100 (v/v), 0.1% -mercaptoethanol (v/v), and a
protease inhibitors mixture (Roche, Basel, Switzerland). The
final protein concentration was determined using the BCA kit
(Pierce, Rockford, IL). Sixty g of each protein lysate were
electrophoresed in 4 –12% polyacrilamide NuPAGE gels (In-
Fig. 1 mRNA expression of
CL100/mitogen-activated pro-
tein kinase phosphatase 1
(MKP-1) in human lung cancer
cell lines. A, CL100/MKP-1
mRNA of different cancer cell
lines [small cell lung cancer
(SCLC) and non-small cell lung
cancer (NSCLC)] and of pri-
mary bronchial epithelial cells
[normal human bronchial epi-
thelium (NHBE)]. B, the table
represents normalization of
CL100/MKP-1 mRNA using ri-
bosomal protein S9. The results
shown are from one experiment
of three performed, obtaining
similar results. The asterisk in-
dicates two carcinoid cell lines.
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vitrogen) and transferred to a polyvinylidene difluoride Im-
mobilon P membrane (Millipore, Bedford, MA) according to
the manufacturer’s instructions. Membranes were probed
with a specific anti-MKP-1 antibody (Santa Cruz Biotech-
nology), anti-phospho-ERK, anti-total-ERK, anti-phospho-
JNK, anti-total-JNK, anti-phospho-p38 anti-total-p38 (Cell
Signaling), and anti--actin (Sigma, St. Louis, MO). The
Lumilight kit (Roche) was used to visualize immunoreaction
in Hyperfilm enhanced chemiluminescence films (Amersham
Biosciencies).
Statistical Analysis. Statistical analysis was performed
using the SPSS Data Analysis Program, version 9.0. The tests
used were the 2 test, two tailed, for dicotonomous variables;
the Mann-Whitney test, two tailed, for continuous variables; and
the Kaplan-Meier survival plot, the log-rank test, and the Cox
regression for survival analysis.
Fig. 2 CL100/mitogen-activated protein kinase phosphatase 1 (MKP-1) protein expression and mitogen-activated protein kinase activation in small
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines. A, Western blots of SCLC cell lines as compared with NSCLC cell lines.
The asterisk indicates two carcinoid cells. B, a and b are SCLC cell lines immunostained for CL100/MKP-1 showing low levels of the phosphatase.
Arrows point at a single weak immunostained cell in B. c and d are NSCLC cell lines showing strong CL100/MKP-1 staining.
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RESULTS
CL100/MKP-1 mRNA Differential Expression in Lung
Tumor Cell Lines. We evaluated CL100/MKP-1 gene ex-
pression levels in NHBE cells and in lung cancer cell lines by
Northern blot analysis. A 2.4-Kb band corresponding to the
CL100/MKP-1 mRNA was detected in all cell lines. mRNA
expression levels were different among SCLC (n  7) and
NSCLC (n  8) cell lines. SCLC cells showed equal or lower
CL100/MKP-1 mRNA levels than control NHBE cells. In
contrast, NSCLC cell lines studied expressed higher levels of
CL100/MKP-1 mRNA (at least twice the levels of NHBE),
except for Calu3, HTB58, and H157, in which the levels
remained similar to those of NHBE (Fig. 1).
CL100/MKP-1 Protein Expression in Lung Tumor Cell
Lines. Total protein extracts of SCLC and NSCLC cell lines
were assessed by Western blot. Similar to what we found for
CL100/MKP-1 mRNA levels, NSCLC and SCLC showed
different patterns of CL100/MKP-1 protein expression. In
most SCLC cell lines, protein levels were low (H345,
H446, H69, and H774) or undetectable (H82). CL100/MKP-1
expression was found in all NSCLC cell lines, and 5 of 9 cell
lines (H1264, A549, H441, H23, H441, and H727) showed
high protein expression. In general, protein levels in NSCLC
and carcinoid cell lines correlated with mRNA (Fig. 2A).
CL100/MKP-1 Protein Localization in Lung Tumor
Cell Lines. Intracellular localization of CL100/MKP-1 pro-
tein was assessed in 15 cell lines (6 SCLCs and 9 NSCLCs) by
immunohistochemistry (Table 1 and Fig. 2B). Higher protein
levels were found in NSCLC cell lines when compared with
those of SCLC. In NSCLC and SCLC cells immunostaining was
located both in the nucleus and in the cytoplasm.
CL100/MKP-1 Protein Expression in Normal and Tu-
mor Tissues: Overexpression in NSCLC. CL100/MKP-1
protein expression in normal lung areas and lung tumor
tissues was evaluated by IHC. Firstly, we assessed 30 spec-
imens of distant normal lung obtained from surgical speci-
mens of lung cancer patient tumors. The normal epithelial
tissue was considered negative regarding the cutoff used for
this molecular marker. In normal alveoli, CL100/MKP-1
protein expression was undetectable in type I and type II
pneumocytes (Fig. 3A). However, in the normal bronchial
epithelium, present in 12 of 30 biopsies, some ciliated cells
(20 – 40%) showed nuclear staining (12 of 12 cases studied;
Fig. 3B). In 10 cases, a light cytoplasmic staining was also
found in ciliated cells. Macrophages, endothelial cells, and
smooth muscle cells were also stained. Smooth muscle stain-
ing was used as an internal positive control for the IHC
technique.
We also assessed the expression of CL100/MKP-1 in type
II cell hyperplasias found in alveolar fields close to the tumor.
Alveolar hyperplasias (n  14) were positive in all specimens
studied (the proportion of type II cells that were positive was
50–70%). Immunostaining was found predominantly in the
nucleus (Fig. 3C).
Finally, we evaluated NSCLC clinical specimens (n 
108). CL100/MKP-1 immunostaining was widely distributed in
this type of tumor. All tumor specimens showed expression of
the phosphatase. Seventy-eight percent of cases (93% of the
adenocarcinomas and 74% of the squamous cell carcinomas)
were considered positive for clinical correlation purposes ac-
cording to the cutoff selected previously. Generally, immuno-
staining was found both in the nucleus and in the cytoplasm
(Fig. 3C).
MAPK Activation in Lung Cancer Cell Lines. Analy-
sis of MAPK activation in the cell lines by Western blot analysis
showed that all three proteins were activated both in SCLC and
NSCLC cell lines, although activation levels were different
among cell lines (Fig. 2A). Concerning SCLC, ERK activation
was shown in all cell lines, P-JNK in 5 of 7 and P-p38 in 7 of
7. In NSCLC, P-ERK was found in all cell lines, P-JNK in 5 of
7 cell lines and P-p38 in 5 of 7. We did not observe any evident
correlation between CL100/MKP-1 protein levels and activation
of ERK, JNK, and p38 when individual cell lines were com-
pared, the only exception being an apparent inverse correlation
between CL100/MKP-1 expression and p38 phosphorylation in
SCLC.
P-JNK and P-p38 Protein in Normal and NSCLC Tis-
sues: Activation in Tumor Tissue. We also assessed the
phosphorylation of the stress-activated MAPKs, JNK and p38
(Figs. 4 and 5). Data for P-ERK are published in a separate
study (33) and will be mentioned in the discussion for com-
parison purposes. JNK activation was found predominantly in
the ciliated cells of the normal bronchiolar epithelium (60 –
85% of cytoplasms and 25–50% of the nuclei of these cells)
but not in the alveolar epithelial cells (Fig. 4, A and C). P-p38
was not found either in the alveolar or in the bronchiolar
epithelial cells (Fig. 4, B and D). Other cell types such as
fibroblasts, endothelial cells, and smooth muscle cells
showed JNK but no p38 activation. In type II alveolar hy-
perplasia, we found that JNK was activated in the nucleus in
5–10% of type II pneumocytes, whereas p38 was activated in
30% of these cells (Fig. 4, E and F). Fig. 5 shows the
incidence of positive cases in every stage analyzed for the
nuclear activation of JNK and p38, according to the cutoff
used for each MAPK.
When assessing NSCLC specimens, we observed acti-
Table 1 CL100/mitogen-activated protein kinase phosphatase-1
expression in lung cancer cell lines
Cell lines
% positive
cells Staining localization
Small cell lung cancer (n  6)
H69 20% Nuclear
H82 20% Nuclear
H187 10% Nuclear
H345 40% Nuclear
H446 55% Nuclear/cytoplasmic
H510 30% Nuclear/cytoplasmic
Non-small cell lung cancer (n  9)
H23 55% Nuclear
H441 80% Nuclear/cytoplasmic
A549 75% Nuclear/cytoplasmic
H676 60% Nuclear/cytoplasmic
H720a 60% Nuclear/cytoplasmic
H727a 80% Nuclear/cytoplasmic
H1264 85% Nuclear/cytoplasmic
H1385 70% Nuclear
HTB58 70% Nuclear
a H720 and H727 are carcinoid cells.
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vation of both JNK and p38 in 57 of 70 and 45 of 70 of the
tumor specimens, respectively (Fig. 4, G and H). In 15 of
P-p38-positive specimens, most of the immunostained carci-
noma cells were found at the periphery of the tumor, as
previously had been found for P-ERK activation (33). The
immunocytochemical signal of phosphorylation of these
MAPKs was found both in the nucleus and the cytoplasm of
the tumor cells.
Prognostic Value of CL100/MKP-1 in NSCLC. The
characteristics of the 70 patients with clinical follow-up are
shown in Table 2. The relationships between CL100/MKP-1
nuclear expression, P-ERK (nuclear and cytoplasmic activa-
tion), P-JNK, and p38 (nuclear activation), and several clinico-
pathological factors are shown in Table 3. CL100/MKP-1 ex-
pression was associated with tumor type (adenocarcinoma; P 
0.04) in an univariate analysis. No association between the
phosphatase expression and either clinicopathological variables
or MAPKs IHC patterns was observed.
We also performed the patient survival analysis. Kaplan-
Meier plots of all patients with clinical follow-up whose
tumors had positive nuclear staining for CL100/MKP-1
(50% tumor nuclei stained) and of those whose tumors
were negative (50% tumor nuclei stained) were carried out.
The survival analysis showed a better outcome of those
patients with positive staining. As Fig. 6A shows, the median
survival of patients with positive nuclear staining has not
been reached, whereas in patients with negative nuclear stain-
ing tumors, the median survival was 30 months (P  0.009;
log rank). An additional subgroup analysis limited to patients
with early-stage (I or II) tumors showed a trend between the
CL100/MKP-1 expression and an improved survival of bor-
derline significance (P  0.059; Fig. 6B). Multivariate Cox
regression analysis showed that the association between sur-
vival and phosphatase expression was maintained when
adjusted for tumor stage (P  0.014). Hazard ratio of death
for negative staining was 3.12 (95% confidence interval
1.25– 8-33).
JNK Activation Is Associated with Early Stages and
Lower T. We also studied the influence of MAPKs activation
on the clinical outcome of the tumors (Table 3). First, we found
that ERK was associated with advanced stage and also with
higher T and N. Second, nuclear JNK activation was associated
with early-stage (P  0.006) tumors and lower T (P  0.001)
and also with histology (P  0.02). Finally, P-p38 directly
associated with nuclear (P  0.001) and cytoplasmic ERK
activation (P  0.002).
We also performed Kaplan-Meier plots to assess the
influence of each MAPK activation in NSCLC patients. Uni-
Fig. 3 Immunohistochemistry for anti-CL100/mitogen-activated protein kinase phosphatase 1 (MKP-1). Examples of normal lung tissue areas
immunostained with an anti-CL100/MKP-1 antibody. Alveoli (A) and bronchus (B) are shown. Alveolar cells are negative for CL100/MKP-1 staining
(arrows). Some ciliated and basal cells are positive in bronchial epithelium (arrows), as well as smooth muscle and fibroblasts (arrowheads). C, type
II hyperplasia is shown. Nuclei of hyperplastic pneumocytes are immunostained (arrows), as well as nonepithelial cells (arrowheads). D,
adenocarcinoma with nuclear and cytoplasmic staining.
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variate analysis showed that nuclear and cytoplasmic P-JNKs
were potential positive prognostic factors of NSCLC pa-
tients (P  0.03). No influence on survival was observed
for any of the three MAPK in the multivariate analysis,
although nuclear P-JNK showed a trend toward significance
(P  0.12).
DISCUSSION
CL100/MKP-1 regulates the activity of the different
MAPKs, but little is known about its expression and biolog-
ical role in lung tumorigenesis. In the present study, we
reported a differential expression of CL100/MKP-1 in vitro
between the two major types of lung cancer. In general,
Fig. 4 Immunohistochemistry for anti-
P-c-jun NH2-terminal kinase (P-JNK)
and anti-P-p38. Normal alveolar and
bronchiolar epithelium immunostained
for P-JNK (A and B) and P-p38 (C and
D). C, immunostaining is only observed
in bronchial epithelium stained with P-
JNK. E and F, type II hyperplasias for
P-JNK and P-p38. Arrows point to some
positive pneumocytes and arrowheads
to nonepithelial-positive cells. G, squa-
mous carcinoma immunostained for P-
JNK. H, adenocarcinoma immuno-
stained for P-p38.
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constitutive levels of the phosphatase in NSCLC were higher
than those found in SCLC cell lines and in normal cells in
basal growth conditions.
In clinical specimens, previous data had suggested an over-
expression of the CL100/MKP-1 protein in tumors such as
breast, colon, and prostate (18) and a decrease from normal to
tumor tissue in ovarian cancer (20). Our present results in
NSCLC were similar to what had been published in breast
tumors where an overexpression of the phosphatase was main-
tained in late stages of the disease (18).
In our IHC survey of normal lung tissue, we found most
of the CL100/MKP-1 expression in nonepithelial cells,
whereas normal bronchiolar and alveolar epithelial cells
show limited or no expression of the phosphatase. These
results suggest that the previous study of high CL100/MKP-1
levels in normal lung extracts (10) may be mainly related to
the relative abundance of nonepithelial cells, stressing the
importance of studying cell type localization when assessing
gene expression. In addition, no expression of CL100/MKP-1
in preneoplastic lesions had been described thus far. In this
work, we showed that CL100/MKP-1 proteins increased in
epithelial hyperplastic lesions such as type II hyperplasia
with respect to normal tissue. Depending on its nuclear
atypia, type II cell hyperplasia has been considered either
an early event in NSCLC carcinogenesis (39) or a reactive
lesion (40).
MAPK activation had been previously studied in lung
tumor cells in vitro (41–46), but only basal ERK activation was
analyzed in detail in a large panel of lung cancer cell lines (47).
Thus far, simultaneous evaluation of ERK, JNK, and p38 acti-
vation has not been performed in lung cancer either in a relevant
number of cell lines or in clinical specimens. In a previous
study, Greenberg et al. (37) reported p38 activation in a short
number of NSCLC patients (n  19), but they did not observe
either ERK or JNK activation in these specimens. In the present
work, we observed the activation patterns of the three MAPKs
in a panel of 17 lung cancer cell lines and 70 NSCLC biopsies.
In the clinical specimens, we found an increase in the nuclear
activation of both JNK and p38 in the tumor when compared
with normal lung in the same way as we recently described for
ERK (33).
We have identified an association between high CL100/
MKP-1 expression levels and better survival in NSCLC (Table
4 and Fig. 6), even for early-stage patients. Our results are not
what would be expected if CL100/MKP-1 would exclusively be
involved in the down-regulation of JNK-mediated apoptosis
(17). It has been shown in several cell types, including tumor
cells, that CL100/MKP-1 down-regulates the activation of the
three MAPKs in the absence (20) or presence of several extra-
cellular stimuli (17, 48, 49). Better survival of patients with
higher levels of CL100/MKP-1 may be because of CL100/
MKP-1 down-regulating mitogenic-inducing ERK activity (20).
On the other hand, biological responses attributed to JNK acti-
vation include not only apoptosis but DNA repair, apoptosis
inhibition, and neoplastic transformation (50). In this regard,
CL100/MKP-1 could also inhibit the phospho-JNK-dependent
growth factor-stimulated cell growth (51), as has been described
by Lee et al. (49), who have suggested that in NSCLC an
increased expression of MKP-1 is involved in the retinoid acid
inhibition of serum-induced growth-promoting JNK phospho-
rylation.
Deactivation of JNK has been previously described in
prostate (34) and colon cancers (35). In the case of prostatic
tumors, the authors suggested that JNK deactivation in ad-
vanced stage tumors could be related to a lower apoptotic
rate. Our data agree with these findings as we showed an
association between JNK activation and early-stage tumors.
In addition, a trend toward significance when comparing
P-JNK and survival has also been described in our work. In
this regard, phosphorylation of JNK in some NSCLC could
increase the sensitivity of the tumor cell to chemo- or radio-
therapy-induced apoptosis. A larger number of patients is
needed to confirm the relevance of activated JNK in the
survival of NSCLC patients.
One interesting finding in our study has been the lack of
association between CL100/MKP-1 and MAPKs activation.
This fact suggests that the important balance MAPK activa-
tion/dephosphorylation is controlled by more that one factor
and subjected to complex regulation. First, the potential
Table 2 Characteristics of the patients
No. of patients
(n  70)
Percentage
of cases
Age (yrs)
Median 62
Range 31–87
Gender
Male 61 87.1%
Female 9 12.9%
Histology
Adenocarcinoma 32 45.7%
Squamous cell carcinoma 38 53.3%
Stage
Early (I/II) 41 58.6%
Advanced (III/IV) 29 41.4%
T
T1-T2 45 64.3%
T3-T4 25 35.7%
N
N0 39 55.7%
N1-N3 31 44.3%
Fig. 5 Percentage of positive cases for P-c-jun NH2-terminal kinase
(P-JNK) and P-p38 in normal, hyperplastic, and tumor lung tissues. The
final value for each bar accounts for the number of positive specimens
divided by the total of analyzed specimens in each stage of tissue.
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activity of other MKPs such as MKP-3 or MKP-7 (52, 53);
second, the fine-tuned feedback loop consisting of concurrent
CL100/MKP-1 deactivation of the MAPKs (16) and stimu-
lation of the phosphatase transcription by its activated
MAPKs substrates (12); and third, the regulation of CL100/
MKP-1 expression by kinases other than the MAPKs (such
as protein kinases A and C; Refs. 13, 14). This delicate
balance between MKP-1 and its substrates may also lead to
cell-to-cell differences in the phosphatase threshold levels
required for CL100/MKP-1-dependent deactivation of the
MAPKs. This could also explain the lack of association
between the groups of patients classified according to our
arbitrary phosphatase cutoff values and the clinicopatholog-
ical variables.
The best known substrates for JNK and p38 are located
in the nucleus (1). We have clearly found nuclear and cyto-
plasmic immunolocalization of phosphorylated forms of
these two MAPKs in NSCLC. Nuclear and cytoplasmic ac-
tivation of the stressed-related kinases has also been de-
scribed in prostate and colon cancer (34, 35). These results
suggest the existence of noncharacterized cytoplasmic sub-
strates for these MAPKs. In addition, as shown by previous
studies (19, 20), our immunocytochemical results for CL100/
MKP-1 show not only nuclear but also cytoplasmic localiza-
tion of the phosphatase. This finding suggests that CL100/
MKP-1 may be deactivating the MAPKs both in the nucleus
(5) and in the cytoplasm.
In summary, in our work, we have described the involve-
ment of a downstream regulator of MAPKs (CL100/MKP-1)
in NSCLC patient survival, as well as the activation of the
ERK, JNK, and p38 and their relationship with the clinical
outcome. Moreover, these clinical associations reflect the
role of MAPKs in key regulatory mechanisms for NSCLC in
vivo that have already been suggested in vitro (45, 46, 49).
Our observations support the view of CL100/MKP-1 and the
MAPKs as potential targets for lung cancer treatment. It will
be useful in the future to explore whether the phosphatase
expression might account for the response of lung cancer
treatments targeting MAPK activation (38) or upstream ele-
ments of the MAPK cascade like the epidermal growth factor
receptor signaling pathway (54).
Fig. 6 Prognostic relevance of CL100/mitogen-activated protein ki-
nase phosphatase 1 (MKP-1) expression in non-small cell lung cancer.
A, survival plot from patients with clinical follow-up (n  70), repre-
senting CL100/MKP-1 expressing cases (continuous line) versus non-
expressing cases (dashed line). Differences between the two groups are
statistically significant (P  0.009). B, survival plot from early stage
patients that shows CL100/MKP-1-positive cases (continuous line) and
CL100/MKP-1-negative cases (dashed line). Differences between the
two groups are at borderline significance (P  0.059).
Table 3 Clinicopathological factors and their relationship to nuclear CL100/MKP-1a staining
CL100/MKP-1 P-JNK nucleus P-p38 nucleus
Age (yrs) P  0.47 P  0.56 P  0.18
Sex P  0.47 P  0.51 P  1
Histology (adenocarcinomas versus squamous cell carcinoma) P  0.04b P  0.02 P  0.79
Stage (I/II versus III/IV) P  0.62 P  0.006 P  0.61
T (T1–2 versus T3–4) P  0.81 P  0.001 P  0.38
N (N0 versus N1–3) P  0.8 P  0.018 P  0.8
P-ERK nucleus P  1 P  0.59 P  0.002
Cytoplasm P  0.63 P  0.6 P  0.001
P-JNK nucleus P  0.41
P-p38 nucleus P  0.28 P  0.77
a MKP-1, mitogen-activated protein kinase phosphatase-1; JNK, c-jun NH2-terminal kinase; ERK, extracellular signal-regulated kinase.
b Values in boldface indicate significance levels 0.05.
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